On Wednesday, August 2, the FDA convened the Arthritis Advisory Committee (AAC) to evaluate the safety and efficacy of Janssen’s anti-IL-6 monoclonal antibody, sirukumab.

Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases. 

Dr. Jack Cush reviews some of the highlights from the past week at EULAR 2017 - June 16, 2017.

Follow RheumNow's expanded coverage from EULAR 2017 in Madrid.

Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.

Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.

A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.

A retrospective analysis of four European vasculitis trials analyzes the risk venous thromboembolism (VTE) with ANCA-associated vasculitis and shows that CRP, cutaneous and GI involvement and baseline creatinine were most associated with VTE risk.

Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.

Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:

Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.

Rheumatoid arthritis (RA) patients have a higher risk of certain cancers (e.g., skin, lung, lymphoma).  At issue is whether the newer agents modify this risk appreciably.

Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.

Dr. Jack Cush reviews highlights from the past week on RheumNow.

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

Dr. Jack Cush reviews highlights from this week on RheumNow.com

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.

Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.